Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06067009 · ClinicalTrials.gov registry record · NA

Feasibility Trial of a Stakeholder-enhanced Lay-navigator-delivered Intervention (ImPart-Multi)

A NA study, sponsored by University of Alabama at Birmingham.

Completed
Registry status
NA
Development phase
22
Enrollment target

NCT06067009 is a NA study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 22 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06067009, a NA study, has completed, sponsored by University of Alabama at Birmingham.

COMPLETED
Registry status
NA
Development phase
22 participants
Enrollment target

Study Summary

The purpose is to explore the feasibility and acceptability of participation in a decision-support training program led by lay navigators. ImPart-Multi, an education-telehealth-based program, is designed to empower Black chronic kidney disease patients (CKD) and their care partners to seek the resources and support needed to be activated allies when making health-related decisions. Participants, both caregivers and patients, completed surveys at study start and at 12 weeks of enrollment. Patients only, based on random assignment, then completed either 1, 3, or 4 education sessions via telehealth or audio connection. Caregivers were not restricted from attending sessions, but were not required. Both patients and caregivers then repeated survey measures at 12 weeks of enrollment. Caregiver and patient participants also completed an interview to share their thoughts on the version of the program they recieved (patients) caregiver interviews focused on if they were able to review mateirals send to the patient, and/or if they noticed a difference in communication, information sharing, etc. after the patient compelted their session(s), and other factors of interest.

Interventions

  • BEHAVIORAL ImPart-Multi - IMproving the decisional PARTnership of Chronic Kidney Disease Dyads with concurrent metabolic disease

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2024-03-20
Est. Completion 2025-02-25
Phase NA

Sponsor

University of Alabama at Birmingham

1,160 total trials

What the Registry Record Tells You About NCT06067009

The ClinicalTrials.gov registry entry for NCT06067009 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which ImPart-Multi - IMproving the decisional PARTnership of Chronic Kidney Disease Dyads with concurrent metabolic disease is the first listed.

NCT06067009 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT06067009 about?

NCT06067009 is a clinical study titled "Feasibility Trial of a Stakeholder-enhanced Lay-navigator-delivered Intervention (ImPart-Multi)". The purpose is to explore the feasibility and acceptability of participation in a decision-support training program led by lay navigators. ImPart-Multi, an education-telehealth-based program, is designed to empower Black chronic kidney disease patients (CKD) and their care partners to seek the resou...

What is the current status of trial NCT06067009?

This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2024-03-20. Estimated completion is 2025-02-25.

What interventions are being tested in trial NCT06067009?

The interventions under investigation include: ImPart-Multi - IMproving the decisional PARTnership of Chronic Kidney Disease Dyads with concurrent metabolic disease (BEHAVIORAL).

Who is sponsoring clinical trial NCT06067009?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.